(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property **Organization**

International Bureau

(43) International Publication Date 26 December 2019 (26.12.2019)





(10) International Publication Number WO 2019/244082 A3

(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 43/00 (2006,01)

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/IB2019/055178

(22) International Filing Date:

19 June 2019 (19.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 62/687,382

20 June 2018 (20,06,2018) US

(71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: BOITANO, Anthony Edward; 27 Evelyn Road, Waban, Massachusetts 02468 (US). BURGER, Matthew T.; Novartis Institutes For Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). CELLITTI, Susan E.; Novartis Institute For Functional Genomics, Inc., DBA Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). COOKE, Michael Paul; 135 University Avenue, #1, Brookline, Massachusetts 02445 (US). FINNER, Catrin; Morphosys AG, Semmel Weisstrasse7, 82152 Planegg (DE). GEIERS-TANGER, Bernhard Hubert; Novartis Institute For Functional Genomics, Inc., DBA Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). LEE-HOEFLICH, Si Tuen; 41 Sanderson Road, Lexington, Massachusetts 02420 (US). PHAM, Hongngoc Thi; 7572 Charmant Drive, #231, San Diego, California 92122 (US). SCHLEYER, Siew Ho; 2649 Monte Vista Avenue, El Cerrito, California 94530 (US). TISSOT, Kathrin; Morphosys AG, Semmel Weisstrasse7, 82152 Planegg (DE). UNO, Tetsuo; Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). WAN, Yongqin; Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). WEN, Ben; Novartis Institute For Functional Genomics, Inc., DBA Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). ZHANG, Qiang (Alan); Novartis Institutes For Biomedical Research,

Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

- (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
- (88) Date of publication of the international search report: 05 March 2020 (05.03.2020)



(57) Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

International application No PCT/IB2019/055178

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K47/68 A61P43/00 ADD.

C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	WO 2016/164502 A1 (HARVARD COLLEGE [US]; MASSACHUSETTS GEN HOSPITAL [US] ET AL.) 13 October 2016 (2016-10-13) page 2, line 15 - page 3, line 12; page 10, lines 13-23; lines 27-32; page 31, lines 10ff; page 45, line 7 - line 29; page 53, line 4 - line 22; page 59, lines 3-26; page 60, lines 1-5; examples 9-11; page 83, line 20 - line 28; claims 1-3, 57-58, 61.	1-13, 15-36
Y	WO 2015/095301 A2 (IRM LLC; GEIERSTANGER BERNHARD [US] ET AL.) 25 June 2015 (2015-06-25) title; page 189, line 24 - page 190, line 15; claim 1; page 354, penultimate structure/	1-13, 15-36

	-/					
X Further documents are listed in the continuation of Box C. X See patent family annex.						
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family					
Date of the actual completion of the international search 14 November 2019	Date of mailing of the international search report 23/01/2020					
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Burema, Shiri					
Form PCT/ISA/210 (second sheet) (April 2005)						

International application No. PCT/IB2019/055178

INTERNATIONAL SEARCH REPORT

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)						
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:						
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:						
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:						
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).						
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)						
This International Searching Authority found multiple inventions in this international application, as follows:						
see additional sheet						
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.						
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.						
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:						
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13, 15-36(all partially)						
The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees.						

ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	W0 2016/020791 A1 (NOVARTIS AG [CH]; ABRAMS TINYA [US] ET AL.) 11 February 2016 (2016-02-11) cited in the application paragraphs [0001], [0003], [0006], [0022]; pages 6-7, paragraph 26; paragraph [0044]; page 14, paragraph 66 - page 15, paragraph 69; paragraphs [00131], [00192]-[00193], [00296]-[00298], [00402], [00404]; claims (particularly claims 3-4); sequences 178, 173	11,12, 16-20, 24,25
X,P	WO 2018/116178 A1 (NOVARTIS AG) 28 June 2018 (2018-06-28) the whole document	1-13, 15-36
Α	WO 2015/138615 A2 (IRM LLC [US]; GEIERSTANGER BERNHARD HUBERT [US]; OU WEIJIA [US]) 17 September 2015 (2015-09-17) cited in the application page 6, line 15 - page 7, line 14; page 8, line 18 - line 23; page 108, line 17 - page 110, line 9; claims; examples; tables 5,10,11,12,14,18	1-13, 15-36
A	WO 2016/203432 A1 (NOVARTIS AG [CH]; ABRAMS TINYA [US] ET AL.) 22 December 2016 (2016-12-22) pages 6-7, paragraph 26, page 14, paragraph 66 - page 15, paragraph 69, claims	1-13, 15-36
Α	WO 2014/150937 A1 (NOVARTIS AG [CH]; IRM LLC [US] ET AL.) 25 September 2014 (2014-09-25) cited in the application abstract, page 10, paragraph 88 - page 11, paragraph 89, pages 33-34, paragraph 206, page 78, paragraph 316- page 80, paragraph 325; claims	1-13, 15-36
Α	WO 2008/067115 A2 (UNIV LELAND STANFORD JUNIOR [US]; WEISSMAN IRVING L [US] ET AL.) 5 June 2008 (2008-06-05) cited in the application page 3, paragraph 12 - page 4, paragraph 15; page 11, paragraph 39; page 13, paragraph 44; claims	1-13, 15-36
Α	WO 2004/002425 A2 (BIO TRANSPLANT INC [US]) 8 January 2004 (2004-01-08) abstract; claims; examples	1-13, 15-36

C(Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
C(Continua Category*		Relevant to claim No. 1-13, 15-36

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-13, 15-36(all partially)

A conjugate of Formula (I): A-(Lb-(D)n)y, wherein A is an antibody fragment that specifically binds to human cKIT; Lb is a linker; D is a cytotoxic agent of Formula (A) or Formula (B); n and y are integers from 1 to 10

2. claims: 14, 37-41(completely); 1-13, 15-36(partially)

An antibody or antibody fragment that specifically binds to human cKIT such as defined in claims 37-41; a conjugate thereof

Information on patent family members

	T 5.000	<u> </u>	019/0551/6
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016164502 A	1 13-10-2016	AU 2016246707 A1 BR 112017021536 A2 CA 2982115 A1 CN 108137648 A EA 201792211 A1 EP 3280720 A1 JP 2018514520 A KR 20180026370 A US 2016324982 A1 US 2019100593 A1 WO 2016164502 A1	09-11-2017 03-07-2018 13-10-2016 08-06-2018 29-06-2018 14-02-2018 07-06-2018 12-03-2018 10-11-2016 04-04-2019 13-10-2016
WO 2015095301 A	2 25-06-2015	AU 2014364812 A1 BR 112016012538 A2 CA 2930614 A1 CN 105899526 A EA 201691251 A1 EP 3082877 A2 JP 2017503777 A KR 20160098257 A SG 11201604877U A US 2016311853 A1 US 2018244717 A1 US 2019382441 A1 WO 2015095301 A2	07-07-2016 26-09-2017 25-06-2015 24-08-2016 30-11-2016 26-10-2016 02-02-2017 18-08-2016 28-07-2016 27-10-2016 30-08-2018 19-12-2019 25-06-2015
WO 2016020791 A	1 11-02-2016	US 2018193475 A1 WO 2016020791 A1	12-07-2018 11-02-2016
WO 2018116178 A	1 28-06-2018	AU 2017383458 A1 CA 3045592 A1 CL 2019001745 A1 CN 110099697 A CO 2019006455 A2 CR 20190296 A EP 3558389 A1 KR 20190099238 A PE 20191539 A1 TW 201828991 A US 2019321483 A1 WO 2018116178 A1	13-06-2019 28-06-2018 13-09-2019 06-08-2019 28-06-2019 13-09-2019 30-10-2019 26-08-2019 23-10-2019 16-08-2018 24-10-2019 28-06-2018
WO 2015138615 A	2 17-09-2015	AU 2015229463 A1 BR 112016020065 A2 CA 2940451 A1 CN 106659800 A EA 201691827 A1 EP 3129407 A2 JP 2017509337 A JP 2018134080 A KR 20160125515 A SG 112016068500 A US 2017021033 A1 WO 2015138615 A2	15-09-2016 20-02-2018 17-09-2015 10-05-2017 30-01-2017 15-02-2017 06-04-2017 30-08-2018 31-10-2016 29-09-2016 26-01-2017 17-09-2015
WO 2016203432 A	1 22-12-2016	EP 3310813 A1 US 2019194315 A1 WO 2016203432 A1	25-04-2018 27-06-2019 22-12-2016

Information on patent family members

						101,100	1019/0001/6
	ent document in search report		Publication date		Patent family member(s)	_	Publication date
WO	2014150937	A1	25-09-2014	CA CCR CCR EP EP JP JP KRA MX PH	095666 2014235474 112015021134 2903772 2015002246 105007956 20150128 20150128 201591801 2968596 3514178 2701051 6333943 6578406 2016512832 2018123141 20150131173 38396 366978 710929 12015501902 112015063958 2015000396 201446806 2014271688 2015320886 2016330594 2017035905 2018125996 35496 2014150937 201505656	A1 A2 A1 A2 A1 A1 A1 B2 AA A1 BBA A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	04-11-2015 27-08-2015 10-10-2017 25-09-2014 04-12-2015 28-10-2015 29-01-2016 30-05-2016 31-03-2016 20-01-2016 24-07-2019 20-02-2019 30-05-2018 18-09-2019 09-08-2018 24-11-2015 30-04-2018 01-08-2019 23-02-2018 04-01-2016 29-09-2015 03-01-2017 16-12-2014 18-09-2014 12-11-2015 04-02-2016 09-02-2017 10-05-2018 31-10-2014 25-09-2014
WO :	2008067115	A2	05-06-2008	DK EP ES HU US US WO	2088864 2088864 3255061 2642205 E034583 2010226927 2017066834 2018327507 2008067115	A A2 L A1 5 T3 B T2 7 A1 A A1 7 A1	02-10-2017 19-08-2009 13-12-2017 15-11-2017 28-02-2018 09-09-2010 09-03-2017 15-11-2018 05-06-2008
WO :	2004002425	A2	08-01-2004	AU WO	2003245752 2004002425		19-01-2004 08-01-2004
	2017219029	A2	21-12-2017	CA CN EP JP KR	2017204125 2018200503 112018076306 3028134 109661406 3472178 2019522686 20190038537 11201811290 2017360954 2019134217	3 A1 5 A2 4 A1 0 A 3 A2 0 A 7 A 4 A1	26-10-2017 15-02-2018 26-03-2019 21-12-2017 19-04-2019 24-04-2019 15-08-2019 08-04-2019 30-01-2019 21-12-2017 09-05-2019

Information on patent family members

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		WO 2017219029 A2	21-12-2017